Northland Securities analyst Suraj Kalia maintained a Hold rating on Resmed Inc (NYSE: RMD) today and set a price target of $80. The company’s shares opened today at $100.94.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 12.5% and a 60.1% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Apollo Endosurgery Inc, and Edwards Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed Inc with a $93.50 average price target, which is a -7.4% downside from current levels. In a report released today, Needham also maintained a Hold rating on the stock.
.
See today’s analyst top recommended stocks >>
Resmed Inc’s market cap is currently $14.05B and has a P/E ratio of 44.98. The company has a Price to Book ratio of 6.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
